LuigiFMeneghiniMDMBA

PubMed

• Benefits of Electronic Consultations in Improving Diabetes Care Within a Safety-Net Health System.
  Felona Gunawan, Syed Ajaz, Luigi Meneghini, Uma Gunasekaran
  Clinical Diabetes. 2023-01-01
• 42 citations
  Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis
  Rhea E. Powell, Francesco Zaccardi, Christine Beebe, Xin Mei Chen, Alyssa Crawford
  Diabetes, Obesity & Metabolism. 2021-09-01
• 1 citations
  Decolonizing Care at Diagnosis: Culture, History, and Family at an Urban Inter-tribal Clinic
  Carolyn Smith-Morris, Sylvia Rodriguez, Rose Soto, Morningstar Spencer, Luigi F. Meneghini
  Medical Anthropology Quarterly. 2021-09-01

Journal Articles

• Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths Misconceptions and Clinical Realities  
  Brod M, Alolga SL, Meneghini L, The Patient, 6/1/2014
• SOLVE Study Group Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents (OHAs) in routine clinical practice  
  Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL, J Diabetes, 5/1/2014
• A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with ty...  
  DeVries H, Meneghini L, Barnett AH, Reid T, Dain MP, Landgraf W, Vlajnic A, Traylor L, Bergenstal RM, European Endocrinology, 1/1/2014
• Insulin Stacking vs Therapeutic Accumulation: Understanding the Differences  
  Heise T, Meneghini LF, Endocr Pract, 9/1/2013
• Stepwise addition of prandial insulin (commentary)  
  Meneghini LF, The Lancet Diabetes & Endocrinology, 9/1/2013
• Effect of Baseline HBA1C on Glycemic Control and Diabetes Management Following Initiation of Once-Daily Insulin Detemir in Real-Life Clinical Practice  
  Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini L, Svendsen AL, on behalf of the SOLVE Study Group, Endocr Pract, 5/1/2013
• The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time da...  
  Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators, Diabetes Care, 4/1/2013
• Screening, evaluation and management of depression in people with diabetes in primary care  
  Hermanns N, Caputo S, Dzida G, Khunti K, Meneghini, L, Snoek, F, Prim Care Diabetes, 4/1/2013
• Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes  
  Vora J, Bain SC, Damci T, Dzida G, Hollander P, Meneghini LF, Ross SA, Diabetes Metab, 2/1/2013
• Intensifying insulin therapy: what options are available to patients with type 2 diabetes?  
  Meneghini LF, The American Journal of Medicine, 1/1/2013
• Bariatric intervention effective at reversing Type 2 diabetes (commentary)  
  Meneghini L, Evidence Based Medicine, 1/1/2013
• Insulin degludec improves health-related quality of life (SF-36(®) ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-an...  
  Freemantle N, Meneghini L, Christensen T, Wolden ML, Jendle J, Ratner R, Diabet Med, 1/1/2013
• Reshaping diabetes care: the fundamental role of DPP-4 inhibitors and GLP-1 receptor agonists in clinical practice  
  Umpierrez G, Meneghini L, Endocr Pract, 1/1/2013
• Insulin therapy for type 2 diabetes  
  Meneghini LF, Endocrine, 1/1/2013
• Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay  
  Ferroni P, Della-Morte D, Pileggi A, Valente MG, Martini F, La Farina F, Palmirotta R, Meneghini LF, Rundek T, Ricordi C, Guadagni F, Cardiovasc Drugs Ther, 8/1/2012
• The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries  
  Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Mene..., Diabetes Obes Metab, 7/1/2012
• Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice  
  Khunti K, Damci T, Meneghini L, Pan CY, Yale JF, on behalf of the SOLVE Study Group Study of Once Daily Levemir (SOLVETM), Diabetes Obes Metab, 7/1/2012
• Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study  
  Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM, Diabetes Obes Metab, 6/1/2012
• Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis  
  Chaudhuri A, Rosenstock J, DiGenio A, Meneghini L, Hollander P, McGill JB, Dandona P, Ilgenfritz J, Riddle M, Diabetes Metab Res Rev, 1/1/2012
• Insulin Degludec: a novel ultra-long acting basal insulin for use in type 1 and type 2 diabetes  
  Meneghini LF, Miranda-Palma B, Expert Review of Endocrinology & Metabolism, 1/1/2012
• Patients with type 1 diabetes display selective defect in antigen receptor mediated T cell apoptosis  
  Jayaraman S, Balasingh S, Exposito J, Ponte G, Baidal D, Cure P, Hafiz M, Meneghini L, Froud T, Alejandro A, Ricordi C, Open Journal of Biology and Biochemistry, 1/1/2012
• Insulin Adherence Behaviors and Barriers in the Multi-national Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP) Study  
  Peyrot M, Barnett AH, Meneghini LF, Schumm-Drager PM, Diabetic Medicine, 1/1/2012
• Individualizing insulin therapy  
  Meneghini L, Reid T, The Journal of Family Practice, 1/1/2012
• Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes  
  Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI, Diabetoic Medicine, 1/1/2012
• Insulin Degludec in Type 1 Diabetes: a Randomized Controlled Trial of a New generation Ultra-long-acting Insulin Compared to Insulin Glargine  
  Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Rob-erts AP, DeVries JH, Meneghini LF, Diabetes Care, 1/1/2011
• Join now to see all

Books/Book Chapters

• Type 1 Diabetes in Adults: Principles and Practice 
  Chapter: Pathophysiology of Type 1 diabetes 
  Meneghini LFEditors: Jabbour & Stephens.Informa Healthcare USA, Inc, New York, NY2008

Abstracts/Posters

• Reduced risk of hypoglycaemia with insulin degludec vs. insulin glargine in patients with type 2 diabetes and a BMI >30 kg/m2: a meta-analysis of five randomised tr...
  Philis-Tsimikas A, Rodbard HW, Meneghini LF, Kapur K, Endahl L, Russell-Jones DL, World Diabetes Congress, 12/1/2013
• Lower within-subject variability in mean blood glucose concentration with insulin degludec vs. in-sulin glargine: a meta-analysis of patients with T2D
  Meneghini L, Harris S, Evans M, Rasmussen S, Johansen T, Pieber T, World Diabetes Congress, 12/1/2013
• Reduced Risk of Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes and a BMI >30 kg/m(2): A Meta-analysis of 5 Randomized Trials
  Rodbard HW1, Meneghini LF, Russell-Jones DL, Kapur R, Endahl L, Kapor J, Philis-Tsimikas A, Can J Diabetes, 10/1/2013
• Lower within-subject variability in mean blood glucose concentration with insulin degludec vs. in-sulin glargine: a meta-analysis of patients with T2D
  Meneghini L, Harris S, Evans M, Rasmussen S, Johansen T, Pieber T, 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), 9/1/2013
• Lower within-subject variability in mean blood glucose concentration with insulin degludec vs. in-sulin glargine: a meta-analysis of patients with T2D
  Meneghini L, Harris S, Evans M, Rasmussen S, Johansen T, Pieber T, 72nd Scientific Sessions of the American Diabetes Association in Chicago, 6/1/2013
• Local Tolerability of Insulin Degludec is Comparable to Insulin Glargine: A Meta-Analysis of T1DM and T2DM
  Meneghini LF, Schumm-Draeger PM, Harris SB, Kimura Y, Niemeyer M, Christiansen JS, 56th Annual Meeting of the Japan Diabetes Society, 5/1/2013
• Less nocturnal hypoglycemia for insulin degludec vs insulin glargine in subjects with T1DM and baseline A1c 7.5–8.5%
  Eid M, Hirsch IB, Meneghini LF (presenter), Landstedt-Hallin L, Rasmussen S, Vora J, 56th Annual Meeting of the Japan Diabetes Society, 5/1/2013
• Lower within-subject variability in mean blood glucose concentration with insulin degludec vs. insulin glargine: a meta-analysis of patients with type 2 diabetes
  Meneghini L, Harris S, Evans M, Rasmussen S, Johansen T, Pieber T, Diabetologia, 1/1/2013
• Lower within-subject variability in mean blood glucose concentration with insulin degludec vs. insulin glargine: a meta-analysis of patients with T2D
  Meneghini L, Harris S, Evans M, Rasmussen S, Johansen T, Pieber T, Diabetes, 1/1/2013
• Health status in people with type 2 diabetes on basal–oral therapy is significantly improved with insulin degludec vs insulin glargine
  Jendle J, Freemantle N, Meneghini L, Christensen T, Wolden M, Ratner R, Ratner R, European Association for the Study of Diabetes, 10/1/2012
• Less nocturnal hypoglycemia for insulin degludec vs. insulin glargine in subjects with T1DM and baseline A1c of 7.5–8.5%: a meta-analysis
  Hirsch I, Meneghini L, Landstedt-Hallin L, Rasmussen S, Lassota N, Vora J, European Association for the Study of Diabetes, 10/1/2012
• Measurement of depression in adults with diabetes
  Carreira M, Anarte M, Marchante A, Manchola-Orozco C, Gupta A, Pulgaron E, Meneghini L, Delamater A, 12th International Congress of Behavioral Medicine, 8/1/2012
• Local Tolerability of Insulin Degludec is Comparable to Insulin Glargine: A Meta-Analysis of Trials in type 1 and type 2 diabetes
  Meneghini LF, Shumm-Draeger P-M, Harris S, Gall M-A, Lassota N, Christiansen JS, 72nd Scientific Sessions of the American Diabetes Association in Philadelphia, 6/1/2012
• Clinical inertia in people with Type 2 diabetes before insulin initiation in routine clinical practice in the UK versus a global cohort: baseline data from the SOLVETM...
  Vora J, Khunti K, Yale JF, Meneghini LF, Diabetes UK Professional Conference, 3/1/2012
• Local Tolerability of Insulin Degludec is Comparable to Insulin Glargine: A Meta-Analysis of Trials in type 1 and type 2 diabetes
  Meneghini LF, Shumm-Draeger P-M, Harris S, Gall M-A, Lassota N, Christiansen JS, Diabetologia, 1/1/2012
• Measurement of depression in adults with diabetes
  Carreira M, Anarte M, Marchante A, Manchola-Orozco C, Gupta A, Pulgaron E, Meneghini L, Delamater A, International Journal of Behavioral Medicine, 1/1/2012
• The safety and effectiveness of adding once-daily insulin detemir to oral hypoglycemia agents in patients with type 2 diabetes in a clinical practice setting
  Meneghini L, Caputo S, Pan C, Svendsen AL, Khunti K on behalf of the SOLVE Study Group, Diabetes, 1/1/2012
• Health status in people with type 2 diabetes on basal–oral therapy is significantly improved with insulin degludec vs insulin glargine
  Jendle J, Freemantle N, Meneghini L, Christensen T, Wolden M, Ratner R, Diabetologia, 1/1/2012
• Study of Once-Daily Levemir SOLVE): Glycaemic control and impact of once-daily insulin detemir in real-life clinical practice
  Caputo S, Artola S, Meneghini L on behalf of the SOLVE Study Group, International Diabetes Federation scientific meetings, 11/1/2011
• Insulin Degludec in a Flexible Daily Dosing Regimen Provides Similar Glycaemic Control Without Increasing Rates of Hypoglycaemia Compared to Dosing the Same Time Daily...
  Birkeland K, Raz I, Gough S, Atkin S, Shestakova M, Blonde L, Meneghini L, Begtrup K, Jo-hansen T, Bain S, Canadian Diabetes Association scientific meetings, 10/1/2011
• Study of once-daily Levemir (SOLVETM) 2: global baseline data and patterns of oral-antidiabetic drug (OAD) use before and after basal insulin initiation
  Meneghini LF, Khunti K, Yale JF, on behalf of the SOLVE Study Group, 47th EASD (European Association for the Study of Diabetes) Annual Meeting, 9/1/2011
• Meneghini L, Atkin S, Bain S, Gough S, Raz I, Blonde L, Begtrup K, Johansen T, Birkeland K, American Diabetes Association's 71st Scientific Sessions, 6/1/2011
• Primary care physician treatment response to A1C data
  Ryan JG, Meneghini LF, Iglesias AJ, Nolen K, American Diabetes Association's 71st Scientific Sessions, 6/1/2011
• Study of Once-Daily Levemir (SOLVE) 1: Clinical inertia in the initiation of insulin therapy in people with poorly controlled type 2 diabetes in real-life clinical pra...
  Khunti K, Yale JF, Meneghini LF for the SOLVE Study Group, Diabetologia, 1/1/2011
• Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen when compared to insulin glargine once daily at the same tim...
  Atkin SL, Bain SC, Gough S, Shestakova MV, Raz I, Blonde L, Meneghini L, Begtrup K, Johan-sen T, Birkeland KI, Diabetologia, 1/1/2011
• Join now to see all

Lectures

• Inpatient management of diabetes 
  12/1/2013
• Ultra-Long Acting Basal Insulin Analogs: Challenges & Opportunities 
  11/1/2013
• Advances in GLP1 Therapy: Current Agents and Combinations 
  11/1/2013
• New Basal Insulin Analogs and Combination Therapy 
  11/1/2013
• Overcoming Barriers to Basal Insulin Therapy Integrating Patient Education and Novel Delivery Technologies into Clinical Practice 
  10/1/2013
• Individualized diabetes management with modern insulin analogues 
  10/1/2013
• New basal insulins - the longer the better? 
  9/1/2013
• Advancing diabetes treatment and future perspectives – Basal insulin therapy, combining to target: Flexibility in dose timing matching patient needs 
  9/1/2013
• Management of type 1 diabetes and exercise 
  8/1/2013
• Perioperative management of diabetes 
  3/1/2013
• Advances in GLP1 Therapy: Current Agents and What's in the Pipeline 
  2/1/2013
• In-patient and perioperative management of diabetes mellitus 
  11/1/2012
• Evidence-Based Strategies to Improve Glycemic Control in Type 2 Diabetes 
  11/1/2012
• Advances in the diabetes treatment pipeline 
  9/1/2012
• An update on insulin therapies: update on bolus insulins 
  6/1/2012
• An update on insulin therapies: Newer bolus insulins 
  6/1/2012
• New oral agents in diabetes 
  3/1/2012
• Exercise and type 1 diabetes: evidence-based practical management 
  3/1/2012
• Breakfast with the expert 
  3/1/2012
• Exercise and type 1 diabetes 
  1/1/2012
• Insulin: an effective means to manage type 2 diabetes 
  11/1/2011
• Advances in Basal Insulin: Addressing the Barriers to Initiation & Intensification of Diabetes Therapy 
  10/1/2011
• Crew Wellness: Diabetes 
  8/1/2011
• Perioperative management of diabetes mellitus 
  6/1/2011
• When and how to use the different insulins in the treatment of diabetes 
  4/1/2011
• Join now to see all

Other

• Update on the use of detemir insulin in the management of type 2 diabetes 
  Meneghini LF, Sheik A, US Endocrinology
  1/1/2008
• Managing Type 2 Diabetes in Ethnic Minority Populations 
  Kahn K, Meneghini L, Clinical Medicine Today: Diabetes Newsletter
  1/1/2008
• Current Treatment Options for a Type 2 Diabetes Patient Not Controlled on OADs 
  Meneghini LF, Pri-Med Online
  http://www.pri-med.com
  1/1/2008
• Insulin Analog Strategies in Action: Initiating, Titrating, and Advancing Therapy in Type 2 Diabetes: A Case Based Discussion Forum 
  Rolla A, Meneghini L, Jovanovic L, Primary Care Quarterly Special Report
  1/1/2007
• Practical Clinical Considerations in Achieving Tight Glycemic Control 
  Meneghini L, PV Updates: Expert Views on Science that Matters Most
  1/1/2006
• Clinical Endocrinology Update 2003 Syllabus 
  Meneghini L, Insulin Pump Therapy
  1/1/2003
• Diabetes 2000: An update for Wound Healers 
  Meneghini L, Wounds - A Compendium of Clinical Research and Practices
  1/1/1999
• Practical Tools for Glycemic Control in Type 2 Diabetes: Introducing Basal/Bolus Insulin Therapy 
  Meneghini LF, Zisman A
• Join now to see all